GlassScriptPhysician profile
Benjamin C Pottebaum
NPI 1528419066
$5,828.60
in general payments reported to CMS, 2019-2025
27 companies · $1.80 in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $1,127 · 2021: $1,200 · 2022: $1,372 · 2023: $965 · 2024: $224 · 2025: $1.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,316.18 | 2019-2023 | |
| Olympus Corporation of The Americas | $791.83 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $591.95 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $485.50 | 2020-2023 | Trulance, Xifaxan |
| Janssen Biotech, INC. | $386.36 | 2020-2024 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $340.94 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $290.54 | 2022-2024 | Dupixent |
| Ardelyx, INC. | $272.44 | 2022-2023 | Ibsrela |
| Janssen Scientific Affairs, LLC | $250.00 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $240.83 | 2019-2020 | |
| Boston Scientific Corporation | $125.00 | 2021 | |
| Portola Pharmaceuticals, LLC | $115.94 | 2020 | |
| Merck Sharp & Dohme LLC | $114.61 | 2019-2024 | Dificid, Bridion |
| Celgene Corporation | $103.16 | 2021-2023 | Zeposia |
| Pfizer INC. | $71.49 | 2019-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.99 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $58.44 | 2022-2023 | Linzess |
| Genzyme Corporation | $48.76 | 2023-2024 | |
| Baxter Healthcare | $29.37 | 2024 | Perclot |
| E.R. Squibb & Sons, L.L.C. | $22.63 | 2021 | |
| Braintree Laboratories, INC. | $21.03 | 2022 | |
| Organon LLC | $19.76 | 2023 | Renflexis |
| Amgen INC. | $17.06 | 2022 | |
| Shionogi INC | $16.64 | 2019 | |
| Ferring Pharmaceuticals INC. | $13.27 | 2023 | Rebyota |
| Redhill Biopharma INC. | $13.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $1.80 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Pottebaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.